Updated: FDA will reclassify at least a dozen peptides, teeing up potential telehealth winnews2026-04-15T19:12:44+00:00April 15th, 2026|Endpoints News|
Replimune looks ahead as repeat CRL speeds the company’s declinenews2026-04-14T17:19:37+00:00April 14th, 2026|Endpoints News|
J&J increasingly confident it can manage Stelara cliff, but work remainsnews2026-04-14T14:47:25+00:00April 14th, 2026|Endpoints News|
FDA approves Travere’s Filspari as first drug for the kidney disease FSGSnews2026-04-14T09:02:09+00:00April 14th, 2026|Endpoints News|
White House policies are ‘incredibly worrisome’ for small biotechs, Rhythm CEO says news2026-04-13T18:52:23+00:00April 13th, 2026|Endpoints News|
Revolution Medicines’ pancreatic cancer drug doubles survival time in Phase 3news2026-04-13T12:00:21+00:00April 13th, 2026|Endpoints News|
Plan for remade ACIP panel adds focus on vaccine safety, matching Kennedy’s pushnews2026-04-10T19:00:33+00:00April 10th, 2026|Endpoints News|
Bayer pharma executive predicts US-Europe price spreads will narrownews2026-04-10T18:28:15+00:00April 10th, 2026|Endpoints News|
FDA rejects Replimune cancer therapy, saying company didn’t resolve trial doubtsnews2026-04-10T16:16:03+00:00April 10th, 2026|Endpoints News|
FDA plans another safety study of abortion drug after court ordernews2026-04-09T18:29:48+00:00April 9th, 2026|Endpoints News|
